BioLargo (BLGO) 10-Q 14 Nov 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 11, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'BIOLARGO, INC.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	82,074,237
Amendment Flag	'false	'
Entity Central Index Key	'0000880242	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
CURRENT ASSETS	'	'
Cash and cash equivalents	$151,660	$92,437
Accounts receivable, net of allowance	4,707	3,929
Inventory	62,676	29,830
Prepaid expense	45,000	'
Total current assets	264,043	126,196
OTHER ASSETS, net of amortization	32,807	40,997
TOTAL ASSETS	296,850	167,193
CURRENT LIABILITIES	'	'
Accounts payable and accrued expenses	420,930	407,157
Note payable	50,000	325,000
Customer deposit	151,699	'
Total current liabilities	622,629	732,157
TOTAL LIABILITIES	622,629	732,157
STOCKHOLDERS’ EQUITY (DEFICIT)	'	'
Convertible Preferred Series A, $.00067 Par Value, 50,000,000 Shares Authorized, -0- Shares Issued and Outstanding, at December 31, 2013 and September 30, 2014.	'	'
Common Stock, $.00067 Par Value, 200,000,000 Shares Authorized, 75,123,014 and 82,074,237 Shares Issued, at December 31, 2013 and September 30, 2014.	54,732	50,069
Additional Paid-In Capital	77,821,109	74,849,492
Accumulated Deficit	-78,274,871	-75,327,603
Non-controlling interest	73,251	-136,922
Total Stockholders’ Equity (Deficit)	-325,779	-564,964
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$296,850	$167,193

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Convertible Preferred Stock, Par Value (in Dollars per share) (in Dollars per share)	$0.00	$0.00
Convertible Preferred Stock, Shares Authorized	50,000,000	50,000,000
Convertible Preferred Stock, Shares Issued	0	0
Convertible Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value (in Dollars per share) (in Dollars per share)	$0.00	$0.00
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares Issued	82,074,237	75,123,014

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue	'	'	'	'
License revenue	'	'	'	$100,000
Product revenue	16,448	18,418	46,821	52,764
Total revenue	16,448	18,418	46,821	152,764
Cost of goods sold	7,731	8,381	19,194	23,563
Gross margin	8,717	10,037	27,627	129,201
Costs and expenses	'	'	'	'
Selling, general and administrative	652,432	536,026	2,208,461	1,470,936
Research and development	186,973	267,861	479,954	603,568
Amortization and depreciation	2,730	2,730	8,190	8,190
Total costs and expenses	842,135	806,617	2,696,605	2,082,694
Loss from operations	-833,418	-796,580	-2,668,978	-1,953,493
Interest expense, net	-3,665	-2,528	-313,117	-240,556
Net loss	-837,083	-799,108	-2,982,095	-2,194,049
Net loss (non-controlling interests)	-10,621	-18,951	-34,827	-311,457
Net loss (controlling interests)	($826,462)	($780,157)	($2,947,268)	($1,882,592)
Loss per common share – basic and diluted (in Dollars per share)	($0.01)	($0.01)	($0.04)	($0.03)
Weighted average common share equivalents outstanding (in Shares)	81,226,826	73,178,574	79,270,195	72,416,712

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) (USD $)

Consultants [Member]

Consultants [Member]

Consultants [Member]

Officers [Member]

Officers [Member]

Officers [Member]

Officers and Board of Directors [Member]

Officers and Board of Directors [Member]

Summer 2013 [Member]

Summer 2013 [Member]

Summer 2013 [Member]

Summer 2014 Offering [Member]

Summer 2014 Offering [Member]

Summer 2014 Offering [Member]

Clyra Spring 2014 Private Securities Offering [Member]

Clyra Spring 2014 Private Securities Offering [Member]

Winter 2012 Warrants [Member]

Winter 2012 Warrants [Member]

Winter 2012 Warrants [Member]

Summer 2013 Warrants [Member]

Summer 2013 Warrants [Member]

Summer 2013 Warrants [Member]

Clyra 2012 PPM Terms [Member]

Clyra 2012 PPM Terms [Member]

Common Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

Noncontrolling Interest [Member]

Conversion of Notes Payable and Related Accrued Interest [Member]

Summer 2013 [Member]

Summer 2014 Offering [Member]

Total

Common Stock [Member]

Additional Paid-in Capital [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Noncontrolling Interest [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Conversion of Notes Payable and Related Accrued Interest [Member]

Conversion of Notes Payable and Related Accrued Interest [Member]

Summer 2013 [Member]

Summer 2014 Offering [Member]

Balance at Dec. 31, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$50,069

'

'

'

$74,849,492

($75,327,603)

($136,922)

'

'

'

($564,964)

Balance (in Shares) at Dec. 31, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,123,014

'

'

'

'

'

'

'

'

'

'

Issuance of stock for cash other than for services or warrants

'

'

'

'

'

'

'

'

2,234

795,266

797,500

309

181,691

182,000

'

'

'

'

'

'

'

'

201

-201

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock for cash other than for services or warrants (in Shares)

'

'

'

'

'

'

'

'

3,328,400

'

'

459,688

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss for the nine-month period ended September 30, 2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,947,268

-34,827

'

'

'

-2,982,095

Fees paid

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-10,000

-20,000

'

'

'

'

-10,000

-20,000

'

Issuance of stock to convert Note Payables and related accrued interest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

911

'

583,889

'

'

'

'

'

584,800

'

'

'

Issuance of stock to convert Note Payables and related accrued interest (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,360,000

'

'

'

'

'

'

'

'

'

'

'

Cash received from Clyra Spring 2014 PPM

'

'

'

'

'

'

'

'

'

'

'

'

'

'

245,000

245,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock for cash received from Warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

263

196,881

197,144

188

83,812

84,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock for cash received from Warrant (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

394,288

'

'

280,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock

302

313,267

313,569

227

179,966

180,193

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock (in Shares)

450,005

'

'

336,967

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of options

'

298,413

298,413

'

'

'

368,661

368,661

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock for option conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28

'

'

'

-28

'

'

'

'

'

'

Issuance of stock for option conversion (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

41,875

'

'

'

'

'

'

'

'

'

41,875

Balance at Sep. 30, 2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$54,732

'

'

'

$77,821,109

($78,274,871)

$73,251

'

'

'

($325,779)

Balance (in Shares) at Sep. 30, 2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

82,074,237

'

'

'

'

'

'

'

'

'

'

Consolidated_Statement_of_Stoc1

Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals) (USD $)	Sep. 30, 2014
Summer 2013 [Member] | Common Stock [Member]	'
Stock price	$0.25
Summer 2013 [Member]	'
Stock price	$0.25
Summer 2014 Offering [Member] | Common Stock [Member]	'
Stock price	$0.40

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net Loss	($2,982,095)	($2,194,049)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:	'	'
Amortization and depreciation expense	8,190	8,190
Increase (decrease) in cash from change in:	'	'
Accounts receivable	-778	10,338
Inventory	-32,846	18,061
Prepaid expenses	-45,000	-3,575
Customer deposit	151,699	'
Other assets	'	-100,000
Accounts payable and accrued expenses	65,251	126,140
Deferred revenue	'	-18,997
Net Cash Used In Operating Activities	-1,416,421	-991,207
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Net cash provided by financing activities	1,475,644	893,500
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	59,223	-97,707
CASH AND CASH EQUIVALENTS b BEGINNING	92,437	151,189
CASH AND CASH EQUIVALENTS b ENDING	151,660	53,482
Cash Paid During the Period for:	'	'
Interest	6,733	'
Taxes	2,400	2,782
Conversion of obligations to shares of our common stock	'	'
Conversion of Note payables and related accrued interest	584,800	'
Fees paid as part of our private security offerings	34,600	76,500
Fair value of the Winter 2012 warrant extension	'	233,000
Officers and Board of Directors [Member]	'	'
Increase (decrease) in cash from change in:	'	'
Non-cash expense related to options issued to board of directors	368,661	252,700
Non-cash expense stock issued	155,011	289,698
Consultants [Member]	'	'
Increase (decrease) in cash from change in:	'	'
Non-cash expense stock issued	305,499	57,516
Stock [Member]	'	'
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Net proceeds from the sale of stock	1,230,644	682,500
Stock in Subsidiary [Member]	'	'
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Net proceeds from the sale of stock	245,000	211,000
Warrant [Member]	'	'
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:	'	'
Non-cash expense	'	233,000
Common Stock [Member]	'	'
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:	'	'
Non-cash expense	291,574	'
Vendors [Member]	'	'
Increase (decrease) in cash from change in:	'	'
Non-cash expense stock issued	$298,413	$329,771

Note_1_Business_and_Organizati

Note 1 - Business and Organization	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	Note 1. Business and Organization
	Outlook
	The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of our business. As reflected in the accompanying financial statements, we (BioLargo, Inc., and its subsidiaries, collectively “we” or the “Company”) had a net loss of $2,982,095 for the nine-month period ended September 30, 2014, and at September 30, 2014, we had a working capital deficit of $358,586, current assets of $264,043, and an accumulated stockholders’ deficit of $78,274,871. The foregoing factors raise substantial doubt about our ability to continue as a going concern. Ultimately, our ability to continue as a going concern is dependent upon our ability to attract significant new sources of capital, attain a reasonable threshold of operating efficiencies and achieve profitable operations by licensing or otherwise commercializing products incorporating our technology. The financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.
	We have been, and anticipate that we will continue to be, limited in terms of our capital resources. Our total cash and cash equivalents were $151,660 at September 30, 2014. We generated revenues of $46,821 in the nine-month period ended September 30, 2014, which amount was not sufficient to fund our operations. We generally have not had enough cash or sources of capital to pay our accounts payable and expenses as they arise, and have relied on the issuance of stock options and common stock, as well as extended payment terms with our vendors to operate. We will be required to raise substantial additional capital to expand our operations, including without limitation, hiring additional personnel, additional scientific and third-party testing, costs associated with obtaining regulatory approvals and filing additional patent applications to protect our intellectual property, and possible strategic acquisitions or alliances, as well as to meet our liabilities as they become due for the next 12 months.
	As of September 30, 2014, we had $50,000 principal amount outstanding on a note payable (see Note 10), and $420,930 of outstanding accounts payable. (See Note 9.)
	During the nine-month period ended September 30, 2014, we received an aggregate $1,505,644 gross and $1,475,644 net proceeds pursuant to our private securities offerings, consisting of $162,000 from our Summer 2014 offering, $787,500 from our Summer 2013 offering, $197,144 from the exercise of our Winter 2012 Warrants, $84,000 from the exercise of our Summer 2013 Warrants, and $245,000 from the Clyra Spring 2014 private securities offering. (See Note 4.)
	In the opinion of management, the accompanying condensed consolidated balance sheets and related condensed consolidated statements of operations, cash flows, and stockholders’ equity include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. Actual results and outcomes may differ from management’s estimates and assumptions. Estimates are used when accounting for stock-based transactions, account payables and accrued expenses and taxes, among others.
	The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to Rule 8-03 of Regulation S-X under the Securities Act of 1933, as amended. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for annual financial statements.  In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. We are still operating in the early stages of the sales and distribution process, and therefore our operating results for the nine-month period ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014, or for any other period. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the Company’s audited financial statements and accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2014.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 2. Summary of Significant Accounting Policies
	Inventory
	Inventories are stated at the lower of cost or net realizable value.  Inventories consisted of:
		31-Dec-13		30-Sep-14
	Raw materials	$	26,080	$	57,044
	Finished goods		3,750		5,632
	Total inventory	$	29,830	$	62,676
	Other Assets
	Other Assets consists of payments made to purchase patents related to our efforts in commercializing the ISAN system.
	For the nine-month periods ended September 30, 2013 and 2014 we recorded amortization expense totaling $8,190 and $8,190, respectively.
	We review intangible assets for potential impairment using our best estimates based on reasonable assumptions and projections. An impairment loss to write such assets down to their estimated fair values is necessary if the carrying values of the assets exceed their related undiscounted expected future cash flows. We also determine impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. No impairment has been recorded for the period ended September 30, 2014.  (See Note 3.)
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, uncollectible accounts receivable, asset depreciation and amortization, and taxes, among others.
	Share-based Payments
	All share-based payments to employees, including grants of employee stock options, are recognized in the financial statements based on their fair values.
	For stock issued to consultants and other non-employees for services, we record the expense based on the fair value of the securities as of the date of the stock issuance. The issuance of stock warrants or options to non-employees are valued at the time of issuance utilizing the Black Scholes calculation and the amount is charged to expense.
	During the nine-month periods ended September 30, 2013 and 2014 we recorded an aggregate $11,200 and $25,200 in selling general and administrative expense related to options issued pursuant to the 2007 Plan.
	During the nine-month periods ended September 30, 2013 and 2014 we recorded an aggregate $607,371 and $641,874 in selling general and administrative expense related to options issued outside of the 2007 Plan.
	During the nine-month periods ended September 30, 2013 and 2014 we issued an aggregate 965,660 and 336,967 shares of our common stock to our officers in lieu of accrued and unpaid compensation and unreimbursed expenses totaling $289,689 and $180,193, respectively. (See Note 9).
	During the nine-month periods ended September 30, 2013 and 2014 we issued an aggregate 242,602 and 450,005 shares of our common stock to third party vendors in lieu of accrued and unpaid compensation and unreimbursed expenses totaling $71,621 and $313,569, respectively. (See Note 9).
	On March 28, 2014, we issued an aggregate 1,360,000 shares of our common stock to note payable holders in lieu of $584,800 note payable principal balance and related accrued interest. (See Note 5).
	Non-Cash Transactions
	We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received.
	The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements.
	Revenue Recognition
	Revenues are recognized as risk and title to products transfers to the customer (which generally occurs at the time shipment is made), the sales price is fixed or determinable, and collectability is reasonably assured. We also may generate revenues from royalties and license fees from our intellectual property. Licensees typically pay a license fee in one or more installments and ongoing royalties based on their sales of products incorporating or using our licensed intellectual property. License fees are recognized over the estimated period of future benefit to the average licensee.
	Earnings (Loss) Per Share
	We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the nine-month periods ended September 30, 2013 and 2014, the denominator in the diluted EPS computation is the same as the denominator for basic EPS due to the anti-dilutive effect of the warrants and stock options on the Company’s net loss.
	Recent Accounting Pronouncements
	In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-08 (ASU 2014-08), Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360). ASU 2014-08 amends the requirements for reporting discontinued operations and requires additional disclosures about discontinued operations. Under ASU 2014-08, only disposals representing a strategic shift in operations or that have a major effect on the Company’s operations and financial results should be presented as discontinued operations. ASU 2014-08 is effective for annual periods beginning after December 15, 2014. As the Company is engaged in research and development activities, the Company does not expect the adoption of this guidance to have any impact on the Company’s financial statement presentation or disclosures.
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company does not expect the adoption of this guidance to have any impact on the Company’s financial statement presentation or disclosures.
	In June 2014, the FASB issued Accounting Standards Update No. 2014-10 (ASU 2014-10), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminated the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclosure the risks and uncertainties related to their activities. ASU 2014-10 also eliminated an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 will no longer be required for interim and annual reporting periods beginning after December 15, 2014, and the revised consolidation standards will take effect in annual periods beginning after December 15, 2015. Early adoption is permitted. The adoption of ASU 2014-10 is not expected to have any impact on the Company’s financial statement presentation or disclosures.
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15 (ASU 2014-15), Presentation of Financial Statements – Going Concern (Subtopic 205-10).  ASU 2014-15 provides guidance as to management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures.  In connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued (or at the date that the financial statements are available to be issued when applicable). Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact the adoption of ASU 2014-15 on the Company’s financial statement presentation and disclosures.
	Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Note_3_Customer_Deposit

Note 3 - Customer Deposit	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Deposit Liabilities Disclosures [Text Block]	'
	Note 3. Customer Deposit
	In 2012, we executed a joint venture agreement with Peter Holdings Ltd., the principal funding source of the development of the Isan System, whereby we jointly purchased the intellectual property associated with the Isan System, and agreed to share any royalties from the intellectual property on an equal 50/50 basis. In February 2014 we received a deposit of $100,000 from InsulTech Manufacturing, LLC, an Arizona limited liability company d/b/a Clarion Water (“Clarion Water”) towards a worldwide, exclusive license of the Isan System. On August 12, 2014, we entered into a license agreement with Clarion Water in which we granted an exclusive license to commercialize the Isan System. (See Note 12.) The license agreement provides that the $100,000 deposit is non-refundable, and is to be credited to future payments of royalties or sublicense fees due under the license agreement. The agreement further provides for a 10% royalty of licensee’s “net sales revenue”, and 40% of sublicensing fees. Licensee is required to make minimum payments beginning July 1, 2016, of $50,000 per quarter, and we are obligated to share any revenues under the agreement on an equal basis with Peter Holdings Pty. Ltd. The intellectual property subject to the license agreement includes all intellectual property related to the Isan System, including all patents, trademarks, proprietary knowledge, and other similar know-how or rights relating to or arising out of the Isan System or the patents related to the Isan System. The agreement contains other terms and conditions typically found in intellectual property license agreements.
	The remaining customer deposit totaling $51,699 was received for a customer order that had not shipped as of September 30, 2014.

Note_4_Private_Securities_Offe

Note 4 - Private Securities Offerings	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 4. Private Securities Offerings
	Summer 2014 Private Securities Offering
	Pursuant to a private offering of our common stock at a price of $0.40 per share (“Summer 2014 Offering”) that commenced on June 25, 2014, we sold 455,000 shares of our common stock to six accredited investors, and received gross and net proceeds of $182,000 and $162,000, respectively. Fees related to this offering consisted of $20,000 cash payments and the issuance of 4,688 shares of our common stock at an exercise price of $0.40 per share.
	Each purchaser of stock will receive, for no additional consideration, a stock purchase warrant which entitles the holder to purchase a number of additional shares of our common stock equal to the number of shares originally purchased. (See Note 6.)
	Summer 2013 Private Securities Offering
	Pursuant to a private offering of our common stock at a price of $0.25 per share that commenced June 2013, through its expiration on March 31, 2014, we sold 3,450,000 shares of our common stock to 24 accredited investors and received $862,500 gross and $857,000 net cash proceeds from the sales. During the nine-month period ended September 30, 2014, we sold 3,190,000 shares of our common stock and received $787,500 gross proceeds from the sales. Fees related to this offering consisted of $15,500 cash payments, $10,000 of which was paid in 2014, and the issuance of 138,400 shares of our common stock in 2014 at an exercise price of $0.25 per share resulting in $34,600 fair value included in additional paid in capital.
	Each purchaser of stock received, for no additional consideration, a stock purchase warrant which entitles the holder to purchase a number of additional shares of our common stock equal to the number of shares originally purchased. (See Note 6.)
	Clyra Spring 2014 Private Securities Offering
	On February 1, 2014, our subsidiary Clyra (see Note 11) began a private securities offering, selling up to 1,000 shares of its common stock at $1,000 per share. From inception of the offering, Clyra sold 220 shares of its common stock to five accredited investors and received $245,000 gross and net proceeds from the sale.
	Each purchaser of stock received, for no additional consideration, (i) a stock purchase warrant entitling the holder to purchase the same number of shares of Clyra common stock as purchased in the offering for $1,833.33 per share until July 30, 2015, and (ii) a warrant issued by BioLargo that allows the holder to exchange one share of Clyra common stock for 4,000 shares of BioLargo common stock. (See Note 6.)
	Winter 2013 Private Securities Offering
	Pursuant to a private offering of our common stock at a price of $0.30 per share that commenced January 2013, through its expiration on June 14, 2013, we sold 2,333,329 shares of our common stock to 13 accredited investors and received $700,000 gross and $633,000 net proceeds from the sales.
	Each purchaser of stock received, for no additional consideration, a stock purchase warrant entitling the holder to purchase the same number of shares as purchased in the offering, for $0.55 per share until July 30, 2015.
	Clyra Winter 2012 Private Securities Offering
	On December 17, 2012, our subsidiary Clyra (see Note 11) began a private securities offering, selling up to 1,000 shares of its common stock at $1,000 per share. The offering ended December 31, 2013 and Clyra sold an aggregate 240 shares of its common stock to four accredited investors and received $240,000 gross and $236,000 net proceeds from the sale.
	In April 2013, Clyra modified the terms of its offering, such that, in addition to shares of Clyra common stock, each Clyra investor would receive a warrant (“Clyra 2012 Warrants”) to purchase an additional number of shares of Clyra common stock as originally purchased by the investor, at a price of $1,833 per share, until July 30, 2015. The offering terms were also modified to increase the number of shares of BioLargo common stock into which the Clyra investor could convert his or her Clyra shares, from 2,858 to 3,333 and 1/3 shares of BioLargo common stock. The number increased in September 2013 to 4,000 shares of BioLargo common stock. The date until which the investor may tender Clyra shares to BioLargo for conversion was extended to July 30, 2015. The Clyra investors will not receive any further warrants to purchase additional BioLargo common stock.

Note_5_Conversion_of_Notes

Note 5 - Conversion of Notes	9 Months Ended
	Sep. 30, 2014
Conversion Of Notes [Abstract]	'
Conversion Of Notes [Text Block]	'
	Note 5. Conversion of Notes
	On March 26, 2014, we issued an aggregate 1,360,000 shares of our common stock, at a conversion price of $0.25, as payment for an aggregate $275,000 in principal and $65,000 of accrued and unpaid interest expense for three promissory notes (originally issued on June 8, 2010, October 28, 2013, and November 15, 2013, detailed below). Our stock price on the date of issuance was $0.43 per share, resulting in an additional financing costs of $244,800 which was recorded as interest expense.
	On June 8, 2010, we received $100,000 and issued a promissory note with an initial maturity date of December 3, 2010, which accrues interest at a rate of 10%. The noteholder, for no additional consideration, received a stock purchase warrant entitling the holder to purchase 50,000 shares of our common stock, exercisable at $0.50 per share until June 3, 2013. The maturity date of the note was mutually extended to December 3, 2011 and then to December 3, 2012. On December 28, 2012, the noteholder agreed to extend the maturity date of the note to December 3, 2013. As consideration for the extension, we issued the noteholder 60,000 shares of our common stock at $0.25 per share and recorded $15,000 in interest expense, and a warrant to purchase 50,000 shares of common stock at $0.50 cents per share, exercisable until June 3, 2014. The fair value of this warrant totaled $6,805 and was recorded as interest expense. On December 31, 2013, the note holder agreed to extend the maturity date of the note January 14, 2015. As consideration for the extension, we issued the noteholder 60,000 shares of our common stock at $0.25 per share and recorded $15,000 in interest expense, and a warrant to purchase 60,000 shares of common stock at $0.30 cents per share, exercisable until January 14, 2017. The fair value of this warrant totaled $14,412 and was recorded as interest expense. (See Note 6.) On March 26, 2014, this note was paid in full by the issuance of our common stock as detailed above.
	On October 28, 2013, we received $75,000 and issued a promissory note with a maturity date of October 31, 2014, which accrues interest at a rate of 10%. On March 26, 2014, this note was paid in full by the issuance of our common stock as detailed above.
	On November 15, 2013, we received $100,000 and issued a promissory note with a maturity date of November 30, 2014, which accrues interest at a rate of 10%. On March 26, 2014, this note was paid in full by the issuance of our common stock as detailed above.
	For the nine-month period ended September 30, 2013 and 2014 we recorded interest expense of $7,556 and $0, respectively related to these converted notes.

Note_6_Warrants

Note 6 - Warrants	9 Months Ended
	Sep. 30, 2014
Warrants [Abstract]	'
Warrants [Text Block]	'
	Note 6. Warrants
	We have certain warrants outstanding to purchase our common stock, at various prices, as described in the following tables:
		Number of
		Shares			Price Range
	Outstanding as of December 31, 2012		8,390,741		$	0.125 – 2.00
	Issued		2,603,329		$	0.50 – 1.00
	Exercised		—		$	—
	Expired		(1,275,298	)	$	0.50 – 1.00
	Outstanding as of September 30, 2013		9,718,772		$	0.125 – 1.00
		Number of
		Shares			Price Range
	Outstanding as of December 31, 2013		10,618,771		$	0.125 – 1.00
	Issued		4,785,001		$	0.25 – 1.00
	Exercised		(674,288	)	$	0.30 – 0.50
	Expired		(6,291,362	)	$	0.50 – 1.00
	Outstanding as of September 30, 2014		8,438,122		$	0.125 – 1.00
	To determine interest expense related to our outstanding warrants issued in conjunction with debt offerings, the fair value of each award grant is estimated on the date of grant using the Black-Scholes option-pricing model and the calculated value is amortized over the life of the warrant. The determination of expense of warrants issued for services or settlement also uses the option-pricing model. The principal assumptions we used in applying this model were as follows:
		2013			2014
	Risk free interest rate		0.12	%		.09 – 1.55	%
	Expected volatility		113	%		184 – 349	%
	Expected dividend yield		—			—
	Forfeiture rate		—			—
	Contractual life in years		1		1 – 5
	The risk-free interest rate is based on U.S Treasury yields in effect at the time of grant. Expected volatilities are based on historical volatility of our common stock.
	No warrants were issued in conjunction with debt or as compensation during the nine-month periods ended September 30, 2013 and 2014, as such there is no corresponding expense related to the warrants issued. Warrants reflecting those issued in the above tables are set forth immediately below.
	Summer 2014 Warrants
	On June 25, 2014, we began a private offering of our common stock at a price of $0.40 per share. (See Note 4.) Per the terms of the Summer 2014 offering and through the period ended September 30, 2104, we issued warrants to purchase 455,500 shares of our common stock. The warrant is exercisable at $0.75 per share, will expire on July 31, 2019, and is subject to a call provision in the event (i) the closing price of the Common Stock for each of twenty (20) consecutive business days, exceeds $1.50 per share (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and the like after the date of issuance of this Warrant), (ii) the Restricted Stock is subject to resale pursuant to 17 C.F.R. 230.144 (“Rule 144”) or pursuant to any other exemption from registration under to the Securities Act of 1933, as amended and (iii) the Shares underlying the Warrant are registered with the SEC.
	Summer 2013 Warrants
	Pursuant to the terms of our Summer 2013 Offering (see Note 4), since inception in June 2013 through its termination on March 31, 2014, we issued warrants to purchase up to an aggregate 3,370,000 shares of our common stock at an exercise price of $0.30 per share. Of this amount, we issued warrants to purchase up to an aggregate 3,190,000 shares of our common stock during the nine-month period ended September 30, 2014. These warrants are set to expire December 31, 2016.
	During the nine-month period ended September 30, 2014 we sold 280,000 shares of our common stock in exchange for $84,000 from the exercise of our Summer 2013 Warrant.
	Clyra 2014 Warrants
	Pursuant to the terms of the Clyra 2014 Spring Offering (see Note 4), during the nine-month period ended September 30, 2014 we issued warrants to purchase up to an aggregate 980,000 shares of our common stock to the investors in the Clyra 2014 Spring Offering. Pursuant to the terms of the warrant, Clyra investors may tender one share of Clyra common stock for 4,000 shares of BioLargo common stock. These warrants are set to expire July 30, 2015.
	Clyra 2012 Warrants
	In April 2013, Clyra modified the terms of its offering, such that, in addition to shares of Clyra common stock, each Clyra investor would receive a warrant (“Clyra 2012 Warrants”) to purchase an additional number of shares of Clyra common stock as originally purchased by the investor, at a price of $1,833 per share, until July 30, 2015. The offering terms were also modified to increase the number of shares of BioLargo common stock into which the Clyra investor could convert his or her Clyra shares, from 2,858 to 4,000 shares of BioLargo common stock. We have issued warrants to purchase up to an aggregate 960,000 shares of BioLargo common stock to the investors in the Clyra Winter 2012 private securities offering. (See Note 4). The date until which the investor may tender Clyra shares to BioLargo for conversion was extended to July 30, 2015.
	On August 29, 2014, an investor in Clyra exchanged 75 Clyra shares for 300,000 shares of BioLargo’s common stock.
	Winter 2013 Warrants
	Pursuant to the terms of our Winter 2013 Offering (see Note 4), during the three-month period ended March 31, 2013, we issued warrants to purchase up to an aggregate 1,366,664 shares of our common stock to the investors in the Offering at an exercise price of $0.55 per share. These warrants are set to expire June 15, 2015.
	Winter 2012 Warrant
	Pursuant to the terms of our Winter 2012 Offering, during 2012 we issued warrants to purchase up to an aggregate 3,127,914 shares of our common stock to the investors in the Offering. These warrants were set to expire on June 30, 2013 and have an exercise price of $0.50 per share. On June 30, 2013, the expiration date of these warrants was extended by a period of one year, such that the warrants now expired on June 30, 2014.
	During the nine-month period ended September 30, 2014 we sold 394,288 shares of our common stock in exchange for $197,144 from the exercise of aWinter 2012 Warrant. The remaining warrants to purchase 2,533,626 shares of our common stock expired unexercised on June 30, 2014.
	Other Warrants
	On December 31, 2013, the noteholder of our note payable (see Note 11) agreed to extend the maturity date to January 14, 2015. As consideration for the extension, we issued a warrant to purchase 60,000 shares of common stock at $0.30 cents per share, resulting in $14,412 recorded as interest expense upon issuance. The warrant expires on June 15, 2017.

Note_7_Stockholders_Equity

Note 7 - Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 7. Stockholders’ Equity
	Preferred Stock
	Our certificate of incorporation authorizes our Board of Directors to issue preferred stock, from time to time, on such terms and conditions as they shall determine. As of December 31, 2013 and September 30, 2014 there were no outstanding shares of our preferred stock.
	Common Stock
	As of December 31, 2013 and September 30, 2014 there were 75,123,014 and 82,074,237 shares of common stock outstanding, respectively. The increase in shares during the nine-month period ended September 30, 2014 is comprised of the following stock issuances: (i) 3,328,400 shares of our common stock issued in connection with our Summer 2013 Offering, (ii) 1,360,000 shares as of our common stock to convert Note Payables, (iii) 459,688 shares of our common stock issued in connection with our Summer 2014 Offering, (iv) 394,288 shares of our common stock issued from the exercise of our 2012 Warrants, (iv) 300,000 shares of our common stock in exchange for Clyra shares purchased as part of the Clyra 2012 Offering, (v) 280,000 shares of our common stock from the exercise of our Summer 2013 Warrant, (vi) 450,005 shares of our common stock to third-party vendors for services performed, (vii) 41,875 shares of our common stock from the exercise of an option, and (viii) 336,967 shares of our common stock to officers in payment to consultants in lieu of accrued and unpaid obligations.

Note_8_StockBased_Compensation

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block Supplement [Abstract]	'
Compensation and Employee Benefit Plans [Text Block]	'
	Note 8. Stock-Based Compensation and Other Employee Benefit Plans
	2007 Equity Incentive Plan
	On August 7, 2007, and as amended April 29, 2011, our Board of Directors adopted the BioLargo, Inc. 2007 Equity Incentive Plan (“2007 Plan”) as a means of providing our directors, key employees and consultants additional incentive to provide services. Both stock options and stock grants may be made under this plan. The Compensation Committee administers this plan. The plan allows grants of common shares or options to purchase common shares. As plan administrator, the Compensation Committee has sole discretion to set the price of the options. The Compensation Committee may at any time amend or terminate the plan.
	During the nine-month period ended September 30, 2014, we recorded the issuance of options to purchase an aggregate 40,000 shares of our common stock to the independent members of our Board of Directors, pursuant to the terms of the 2007 Equity Plan which calls for an annual automatic issuance. Each board member received an option to purchase 10,000 shares of our common stock, the option vests after a period of one year from the date of grant, expires ten years from the date of issuance, and is exercisable at $0.63 per share, the price of our common stock on the grant date. The fair value of this option totaled $25,200 and was recorded as selling, general and administrative expense.
	During the nine-month period ended September 30, 2013, we recorded the issuance of options to purchase an aggregate 40,000 shares of our common stock to the independent members of our Board of Directors, pursuant to the terms of the 2007 Equity Plan which calls for an annual automatic issuance. Each board member received an option to purchase 10,000 shares of our common stock, the option vests after a period of one year from the date of grant, expires ten years from the date of issuance, and is exercisable at $0.28 per share, the price of our common stock on the grant date. The fair value of this option totaled $11,200 and was recorded as selling, general and administrative expense.
	Activity for our stock options under the 2007 Plan for the nine-month period ended September 30, 2013 and 2014 is as follows:
											Weighted
											Average
		Options			Shares						Price per
		Outstanding			Available			Price per share			share
	Balances as of December 31, 2012		8,518,418			4,260,742		$	0.23 – 1.89		$	0.44
	Granted		40,000			(40,000	)		0.28			0.28
	Exercised		—			—			—			—
	Canceled		—			—			—			—
	Balances as of September 30, 2013		8,561,086			4,420,742		$	0.23 – 1.89		$	0.44
											Weighted
											Average
		Options			Shares						Price per
		Outstanding			Available			Price per share			share
	Balances as of December 31, 2013		8,561,086			4,420,742		$	0.23 – 1.89		$	0.44
	Granted		40,000			(40,000	)		0.63			0.63
	Exercised		—			—			—			—
	Canceled		—			—			—			—
	Balances as of September 30, 2014		8,601,086			4,380,742		$	0.23 – 1.89		$	0.44
	Options issued Outside of the 2007 Equity Incentive Plan
	During the nine-month periods ended September 30, 2013 and 2014 we recorded an aggregate $607,371 and $641,678 in selling general and administrative expense related to options issued outside of the 2007 Plan.
	On September 29, 2014, we issued options to purchase 143,617 shares of our common stock at an exercise price of $0.47 per share to our board of directors in lieu of $45,000 in accrued and unpaid fees. The fair value of the Options totaled $67,500, resulting in $22,500 of additional selling, general and administrative expenses.
	On September 29, 2014, we issued options to purchase 193,511 shares of our common stock at an exercise price of $0.47 per share to vendors in lieu of $67,500 in accrued and unpaid fees. The fair value of the Options totaled $90,950, resulting in $23,450 of additional selling, general and administrative expenses.
	On September 29, 2014, a holder of a stock option issued outside of the 2007 Equity incentive plan choose to exercise the cash-less option and we issued 41,875 shares of our common stock, recorded in additional paid in capital.
	On June 24, 2014, we issued options to purchase 103,847 shares of our common stock at an exercise price of $0.65 per share to our board of directors in lieu of $45,000 in accrued and unpaid fees. The fair value of the options totaled $67,501, resulting in $22,501 of additional selling, general and administrative expenses.
	On June 24, 2014, we issued options to purchase 148,848 shares of our common stock at an exercise price of $0.65 per share to vendors in lieu of $64,500 in accrued and unpaid fees. The fair value of the options totaled $96,750, resulting in $32,250 of additional selling, general and administrative expenses.
	On June 23, 2014, BioLargo, Inc. (the “Company”) and its Chief Financial Officer Charles K. Dargan, II formally agreed to extend the engagement agreement dated February 1, 2008 (the “Engagement Agreement”, which had been previously extended multiple times), pursuant to which Mr. Dargan has been serving as the Company’s Chief Financial Officer. The Engagement Extension Agreement dated as of June 23, 2014 (the “Engagement Extension Agreement”) provides for an additional term to expire January 31, 2015 (the “Extended Term”), and is retroactively effective to February 1, 2014. During the Extended Term, Mr. Dargan shall be compensated through the issuance of an option to purchase 300,000 shares of the Company’s common stock, at a strike price of $0.63 per share, to expire June 23, 2024, and to vest over the term of the engagement with 100,000 shares vested as of June 23, 2014, and the remaining shares to vest 25,000 monthly, provided that the Engagement Extension Agreement with Mr. Dargan has not been terminated prior to each vesting date. During the nine-month period ended September 30, 2014, we recorded $141,000 in selling, general and administrative expense for this option.
	On March 31, 2014, we issued options to purchase 156,888 shares of our common stock at an exercise price of $0.43 per share to our board of directors, in lieu of $45,000 in accrued and unpaid fees. The fair value of the options totaled $67,461, resulting in $22,461 of additional selling, general and administrative expenses.
	On March 31, 2014, we issued options to purchase 78,488 shares of our common stock at an exercise price of $0.43 per share to a vendor, in lieu of $22,500 in accrued and unpaid fees. The fair value of the options totaled $33,750, resulting in $11,250 of additional selling, general and administrative expenses.
	On February 20, 2014, we issued options to purchase 40,000 shares of our common stock at an exercise price of $0.35 per share, set to expire February 20, 2024, and to vest over the term of the agreement. The fair value of the options totaled $14,000 of additional selling, general and administrative expenses.
	On September 30, 2013, we issued options to purchase 1,033,825 shares of our common stock at an exercise price of $0.30 per share to certain vendors and consultants, in lieu of $206,765 in accrued and unpaid fees. The fair value of the options totaled $289,471, resulting in $82,706 of additional selling, general and administrative expenses.
	On September 30, 2013, we issued options to purchase 675,000 share of our common stock at an exercise price of $0.30 per share to certain non-employee members of our board of directors, in lieu of $135,000 in accrued and unpaid fees due for services on our board of directors. The fair value of the options totaled $189,000, resulting in $54,000 of additional selling, general and administrative expenses.
	During the nine-month period ended September 30, 2013, a portion of the option to purchase 300,000 shares of common stock issued to our Chief Financial Officer in exchange for his services pursuant to the July 2013 extension of his engagement agreement vested, resulting in $52,500 of selling, general and administrative expense.
	During the nine-month periods ended September 30, 2013 and 2014, a portion of the option to purchase 800,000 shares of common stock issued to a consultant in exchange for his services pursuant to the August 2011 engagement agreement vested, resulting in $57,000 of selling, general and administrative expense.
	Activity of our stock options issued outside of the 2007 Plan for the nine-month period ended September 30, 2013 and 2014 is as follows:
								Weighted
								Average
		Options						Price per
		Outstanding			Price per share			Share
	Balances as of December 31, 2012		13,338,220		$	0.18 – 1.89		$	0.41
	Granted		2,008,825		$	0.3		$	0.3
	Exercised		—			—			—
	Expired		—			—			—
	Balances as of September 30, 2013		15,347,045		$	0.18 – 1.89		$	0.36
		Options						Weighted
								Average
								Price per
		Outstanding			Price per share			Share
	Balances as of December 31, 2013		16,398,395		$	0.18 – 1.00		$	0.39
	Granted		1,165,199			0.43 – 0.65			0.43 – 0.65
	Exercised		(41,875	)		0.3			0.3
	Expired		—			—			—
	Balances as of September 30, 2014		17,521,719		$	0.18 – 1.00		$	0.4
	We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. The following methodology and assumptions were used to calculate share based compensation for the nine-month period ended September 30:
		2013						2014
		Non Plan			2007 Plan			Non Plan			2007 Plan
	Risk free interest rate		2.64 – 2.66	%		2.19	%		2.54 – 2.73	%		2.63	%
	Expected volatility		928	%		928	%		908 – 935	%		927	%
Expected dividend yield		—			—			—			—
Forfeiture rate		—			—			—			—
Expected life in years		7			7			7			7
Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility.
The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future.
Historically, we have not had significant forfeitures of unvested stock options granted to employees and Directors. A significant number of our stock option grants are fully vested at issuance or have short vesting provisions. Therefore, we have estimated the forfeiture rate of our outstanding stock options as zero.

Note_9_Accounts_Payable_and_Ac

Note 9 - Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	Note 9. Accounts Payable and Accrued Expenses
	Accounts payable and accrued expenses included the following:
		December 31,		September 30,
		2013		2014
	Accounts payable and accrued expenses	$	362,194	$	393,361
	Accrued interest		18,226		10,119
	Officer and board of director payables		26,737		17,450
	Total accounts payable and accrued expenses	$	407,157	$	420,930
	Accounts payable and accrued expenses
	During the nine-month periods ended September 30, 2013 and 2014 we issued an aggregate 242,602 and 450,005 shares of our common stock to vendors and consultants and resulting in an aggregate expense of $71,621 and $313,569, respectively.
	On September 29, 2014 we issued 56,250 shares of our common stock to a company providing ongoing services as payment for services totaling $22,500. The agreement required we issue common stock at a rate of $0.40 per share, the stock price on the grant date was $0.47 per share.
	On September 29, 2014 we issued 52,127 shares of our common stock to a consultant as payment for services totaling $15,638. The agreement required we issue common stock at a rate of $0.30 per share, the stock price on the grant date was $0.47 per share.
	On September 29, 2014 we issued 17,094 shares of our common stock to a company providing ongoing services as payment for services totaling $10,725. The agreement required we issue common stock at a rate of $0.63 per share, the stock price on the grant date was $0.47 per share.
	On September 29, 2014 we issued 11,324 shares of our common stock to consultants providing services as payment for services totaling $10,605. The stock price on the grant date was $0.47 per share.
	On June 26, 2014 we issued 90,000 shares of our common stock to a company providing ongoing services as payment for services totaling $22,500. The agreement required we issue common stock at a rate of $0.25 per share, the stock price on the grant date was $0.63 per share.
	On June 30, 2014, we issued an aggregate 31,096 shares of our common stock to a vendor as payment for services totaling $25,000. Our agreement with the vendor required we issue common stock at a 20 day average price, which in this instance was approximately $0.80 per share.
	On June 24, 2014 we issued 18,594 shares of our common stock to a consultant as payment for services totaling $10,725. The stock price on the grant date was $0.65 per share.
	On June 24, 2014 we issued 11,539 shares of our common stock to a consultant as payment for services totaling $7,500. The stock price on the grant date was $0.65 per share.
	On March 28, 2014 we issued an aggregate 73,444 shares of our common stock to two vendors and per the terms of the agreement, as payment for services totaling $18,225, at an average conversion price of $0.25. The stock price on the grant date was $0.43.
	On March 28, 2014 we issued an aggregate 88,537 shares of our common stock to two vendors, as payment for services totaling $38,070, at a conversion price of $0.43.
	On September 27, 2013, we issued 135,826 shares of our common stock, at a conversion price of $0.27 per share, to certain vendors and consultants, in lieu of $37,091 accrued and unpaid amounts.
	On May 15, 2013, we issued an aggregate 11,112 shares of our common stock, at a conversion price of $0.28, as payment for $3,111 of selling, general and administrative expense.
	On May 15, 2013, we issued an aggregate 53,572 shares of our common stock, at a conversion price of $0.28, as payment for $15,000, of which $11,425 is recorded as selling, general and administrative expense and the remaining $3,575 as prepaid rent.
	On January 4, 2013, we issued an aggregate 42,092 shares of our common stock, at a conversion price of $0.25, as payment for $10,530 of selling, general and administrative expense.
	See also Note 8 for information on options issued to consultants and board of directors in lieu of accounts payable obligations.
	Officer and board of directors payables
	During the nine-month period ended September 30, 2013 and 2014, we issued an aggregate 965,660 and 336,967 shares of our common stock to our officers as payment for accrued and unpaid compensation totaling $289,698 and $180,193, respectively.
	On September 29, 2014, we issued an aggregate 114,015 shares of our common stock to our officers as payment for accrued and unpaid compensation totaling $53,586. The stock was issued at the closing price of the Company’s common stock on the day of issuance, $0.47 per share.
	On June 24, 2104, we issued an aggregate 139,458 shares of our common stock to our officers as payment for accrued and unpaid compensation totaling $90,705. The stock was issued at the closing price of the Company’s common stock on the day of issuance, $0.65 per share.
	On March 28, 2014, we issued an aggregate 83,493 shares of our common stock to an officer as payment for accrued and unpaid compensation totaling $35,902. The stock was issued at the closing price of the Company’s common stock on the day of issuance, $0.43 per share.
	On September 30, 2013, we issued 965,660 shares of our common stock, at a conversion price of $0.30, to three of our executive officers, in lieu of $289,698 in accrued and unpaid salary and unreimbursed expenses. The stock issued to the executive officers is restricted from sale until the earlier of the termination of the executive’s employment, or the filing of a report of a “change in control” on Form 8-K.
	All of these offerings and sales were made in reliance on the exemption from registration contained in Section 4(2) of the Securities Exchange Act and/or Regulation D promulgated thereunder as not involving a public offering of securities.

Note_10_Note_Payable

Note 10 - Note Payable	9 Months Ended
	Sep. 30, 2014
Disclosure Text Block [Abstract]	'
Short-term Debt [Text Block]	'
	Note 10.  Note Payable
	On November 19, 2013, we received $50,000 pursuant to a line of credit whereby we have pledged our inventory and accounts receivable as collateral. The maturity date of the line of credit is May 15, 2015, which accrues interest at a rate of 24%.
	For the nine-month period ended September 30, 2013 and 2014 we recorded interest expense of $0 and $9,828, respectively.

Note_11_NonControlling_Interes

Note 11 - Non-Controlling Interest	9 Months Ended
	Sep. 30, 2014
Noncontrolling Interest [Abstract]	'
Noncontrolling Interest Disclosure [Text Block]	'
	Note 11. Non-Controlling Interest
	In May 2012, we formed a subsidiary for the purpose of marketing and selling medical products containing our technology, Clyra Medical Technology, Inc. (“Clyra”). Until December 17, 2012, this subsidiary was wholly owned, with 7,500 shares issued to BioLargo, Inc. On December 17, 2012, Clyra signed executive employment agreements with three individuals, in which each was granted 500 shares of Clyra common stock, one-third of which vested immediately, and the remaining over time. The shares granted to the three executives are restricted from transfer until a sale of the company, whether by means of a sale of its stock or substantially all of its assets, or otherwise by agreement of Clyra, BioLargo and the executives.
	Clyra has raised $236,000 in proceeds through issuing 240 shares of its common stock during the year ended December 31, 2013 and raised an additional $245,000 in proceeds through issuing 245 shares of its common stock during the nine-month period ended September 30, 2014. (See Note 4.) The holdings of the Clyra executive officers and investors represent 19.6% of the issued and outstanding stock of the company.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Inventory, Policy [Policy Text Block]	'
	Inventory
	Inventories are stated at the lower of cost or net realizable value.  Inventories consisted of:
		31-Dec-13		30-Sep-14
	Raw materials	$	26,080	$	57,044
	Finished goods		3,750		5,632
	Total inventory	$	29,830	$	62,676
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	'
	Other Assets
	Other Assets consists of payments made to purchase patents related to our efforts in commercializing the ISAN system.
	For the nine-month periods ended September 30, 2013 and 2014 we recorded amortization expense totaling $8,190 and $8,190, respectively.
	We review intangible assets for potential impairment using our best estimates based on reasonable assumptions and projections. An impairment loss to write such assets down to their estimated fair values is necessary if the carrying values of the assets exceed their related undiscounted expected future cash flows. We also determine impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. No impairment has been recorded for the period ended September 30, 2014.  (See Note 3.)
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, uncollectible accounts receivable, asset depreciation and amortization, and taxes, among others.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Share-based Payments
	All share-based payments to employees, including grants of employee stock options, are recognized in the financial statements based on their fair values.
	For stock issued to consultants and other non-employees for services, we record the expense based on the fair value of the securities as of the date of the stock issuance. The issuance of stock warrants or options to non-employees are valued at the time of issuance utilizing the Black Scholes calculation and the amount is charged to expense.
	During the nine-month periods ended September 30, 2013 and 2014 we recorded an aggregate $11,200 and $25,200 in selling general and administrative expense related to options issued pursuant to the 2007 Plan.
	During the nine-month periods ended September 30, 2013 and 2014 we recorded an aggregate $607,371 and $641,874 in selling general and administrative expense related to options issued outside of the 2007 Plan.
	During the nine-month periods ended September 30, 2013 and 2014 we issued an aggregate 965,660 and 336,967 shares of our common stock to our officers in lieu of accrued and unpaid compensation and unreimbursed expenses totaling $289,689 and $180,193, respectively. (See Note 9).
	During the nine-month periods ended September 30, 2013 and 2014 we issued an aggregate 242,602 and 450,005 shares of our common stock to third party vendors in lieu of accrued and unpaid compensation and unreimbursed expenses totaling $71,621 and $313,569, respectively. (See Note 9).
	On March 28, 2014, we issued an aggregate 1,360,000 shares of our common stock to note payable holders in lieu of $584,800 note payable principal balance and related accrued interest. (See Note 5).
Non-Cash Transactions [Policy Text Block]	'
	Non-Cash Transactions
	We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received.
	The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	Revenues are recognized as risk and title to products transfers to the customer (which generally occurs at the time shipment is made), the sales price is fixed or determinable, and collectability is reasonably assured. We also may generate revenues from royalties and license fees from our intellectual property. Licensees typically pay a license fee in one or more installments and ongoing royalties based on their sales of products incorporating or using our licensed intellectual property. License fees are recognized over the estimated period of future benefit to the average licensee.
Earnings Per Share, Policy [Policy Text Block]	'
	Earnings (Loss) Per Share
	We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the nine-month periods ended September 30, 2013 and 2014, the denominator in the diluted EPS computation is the same as the denominator for basic EPS due to the anti-dilutive effect of the warrants and stock options on the Company’s net loss.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	In April 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-08 (ASU 2014-08), Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (Topic 360). ASU 2014-08 amends the requirements for reporting discontinued operations and requires additional disclosures about discontinued operations. Under ASU 2014-08, only disposals representing a strategic shift in operations or that have a major effect on the Company’s operations and financial results should be presented as discontinued operations. ASU 2014-08 is effective for annual periods beginning after December 15, 2014. As the Company is engaged in research and development activities, the Company does not expect the adoption of this guidance to have any impact on the Company’s financial statement presentation or disclosures.
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for reporting periods beginning after December 15, 2016, and early adoption is not permitted. Entities can transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company does not expect the adoption of this guidance to have any impact on the Company’s financial statement presentation or disclosures.
	In June 2014, the FASB issued Accounting Standards Update No. 2014-10 (ASU 2014-10), Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. ASU 2014-10 eliminated the requirement to present inception-to-date information about income statement line items, cash flows, and equity transactions, and clarifies how entities should disclosure the risks and uncertainties related to their activities. ASU 2014-10 also eliminated an exception provided to development stage entities in Consolidations (ASC Topic 810) for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The presentation and disclosure requirements in Topic 915 will no longer be required for interim and annual reporting periods beginning after December 15, 2014, and the revised consolidation standards will take effect in annual periods beginning after December 15, 2015. Early adoption is permitted. The adoption of ASU 2014-10 is not expected to have any impact on the Company’s financial statement presentation or disclosures.
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15 (ASU 2014-15), Presentation of Financial Statements – Going Concern (Subtopic 205-10).  ASU 2014-15 provides guidance as to management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures.  In connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued (or at the date that the financial statements are available to be issued when applicable). Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the impact the adoption of ASU 2014-15 on the Company’s financial statement presentation and disclosures.
	Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		31-Dec-13		30-Sep-14
	Raw materials	$	26,080	$	57,044
	Finished goods		3,750		5,632
	Total inventory	$	29,830	$	62,676

Note_6_Warrants_Tables

Note 6 - Warrants (Tables)	9 Months Ended
	Sep. 30, 2014
Warrants [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
		Number of
		Shares			Price Range
	Outstanding as of December 31, 2012		8,390,741		$	0.125 – 2.00
	Issued		2,603,329		$	0.50 – 1.00
	Exercised		—		$	—
	Expired		(1,275,298	)	$	0.50 – 1.00
	Outstanding as of September 30, 2013		9,718,772		$	0.125 – 1.00
		Number of
		Shares			Price Range
	Outstanding as of December 31, 2013		10,618,771		$	0.125 – 1.00
	Issued		4,785,001		$	0.25 – 1.00
	Exercised		(674,288	)	$	0.30 – 0.50
	Expired		(6,291,362	)	$	0.50 – 1.00
	Outstanding as of September 30, 2014		8,438,122		$	0.125 – 1.00
Schedule of Assumptions Used to Determine Fair Value of Warrants [Table Text Block]	'
		2013			2014
	Risk free interest rate		0.12	%		.09 – 1.55	%
	Expected volatility		113	%		184 – 349	%
	Expected dividend yield		—			—
	Forfeiture rate		—			—
	Contractual life in years		1		1 – 5

Note_8_StockBased_Compensation1

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Tables)	9 Months Ended
	Sep. 30, 2014
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Tables) [Line Items]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		2013						2014
		Non Plan			2007 Plan			Non Plan			2007 Plan
	Risk free interest rate		2.64 – 2.66	%		2.19	%		2.54 – 2.73	%		2.63	%
	Expected volatility		928	%		928	%		908 – 935	%		927	%
	Expected dividend yield		—			—			—			—
	Forfeiture rate		—			—			—			—
	Expected life in years		7			7			7			7
2007 Equity Incentive Plan [Member]	'
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Tables) [Line Items]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
											Weighted
											Average
		Options			Shares						Price per
		Outstanding			Available			Price per share			share
	Balances as of December 31, 2012		8,518,418			4,260,742		$	0.23 – 1.89		$	0.44
	Granted		40,000			(40,000	)		0.28			0.28
	Exercised		—			—			—			—
	Canceled		—			—			—			—
	Balances as of September 30, 2013		8,561,086			4,420,742		$	0.23 – 1.89		$	0.44
											Weighted
											Average
		Options			Shares						Price per
		Outstanding			Available			Price per share			share
	Balances as of December 31, 2013		8,561,086			4,420,742		$	0.23 – 1.89		$	0.44
	Granted		40,000			(40,000	)		0.63			0.63
	Exercised		—			—			—			—
	Canceled		—			—			—			—
	Balances as of September 30, 2014		8,601,086			4,380,742		$	0.23 – 1.89		$	0.44
Outside of 2007 Plan [Member]	'
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Tables) [Line Items]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
								Weighted
								Average
		Options						Price per
		Outstanding			Price per share			Share
	Balances as of December 31, 2012		13,338,220		$	0.18 – 1.89		$	0.41
	Granted		2,008,825		$	0.3		$	0.3
	Exercised		—			—			—
	Expired		—			—			—
	Balances as of September 30, 2013		15,347,045		$	0.18 – 1.89		$	0.36
		Options						Weighted
								Average
								Price per
		Outstanding			Price per share			Share
	Balances as of December 31, 2013		16,398,395		$	0.18 – 1.00		$	0.39
	Granted		1,165,199			0.43 – 0.65			0.43 – 0.65
	Exercised		(41,875	)		0.3			0.3
	Expired		—			—			—
	Balances as of September 30, 2014		17,521,719		$	0.18 – 1.00		$	0.4

Note_9_Accounts_Payable_and_Ac1

Note 9 - Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'
		December 31,		September 30,
		2013		2014
	Accounts payable and accrued expenses	$	362,194	$	393,361
	Accrued interest		18,226		10,119
	Officer and board of director payables		26,737		17,450
	Total accounts payable and accrued expenses	$	407,157	$	420,930

Note_1_Business_and_Organizati1

Note 1 - Business and Organization (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Note 1 - Business and Organization (Details) [Line Items]	'	'	'	'	'	'
Retained Earnings (Accumulated Deficit)	($78,274,871)	'	($78,274,871)	'	($75,327,603)	'
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	-837,083	-799,108	-2,982,095	-2,194,049	'	'
Net Assets	-358,586	'	-358,586	'	'	'
Assets, Current	264,043	'	264,043	'	126,196	'
Cash and Cash Equivalents, at Carrying Value	151,660	53,482	151,660	53,482	92,437	151,189
Revenues	16,448	18,418	46,821	152,764	'	'
Long-term Debt, Gross	50,000	'	50,000	'	'	'
Accounts Payable and Accrued Liabilities, Current	420,930	'	420,930	'	407,157	'
Private Placement [Member] | Summer 2014 Offering [Member]	'	'	'	'	'	'
Note 1 - Business and Organization (Details) [Line Items]	'	'	'	'	'	'
Proceeds From Issuance of Private Placement Net	'	'	162,000	'	'	'
Private Placement [Member] | Summer 2013 Offering [Member]	'	'	'	'	'	'
Note 1 - Business and Organization (Details) [Line Items]	'	'	'	'	'	'
Proceeds From Issuance of Private Placement Net	'	'	787,500	'	'	'
Private Placement [Member] | Winter 2012 Warrants [Member]	'	'	'	'	'	'
Note 1 - Business and Organization (Details) [Line Items]	'	'	'	'	'	'
Proceeds From Issuance of Private Placement Net	'	'	197,144	'	'	'
Private Placement [Member] | Summer 2013 Warrants [Member]	'	'	'	'	'	'
Note 1 - Business and Organization (Details) [Line Items]	'	'	'	'	'	'
Proceeds From Issuance of Private Placement Net	'	'	84,000	'	'	'
Private Placement [Member] | Clyra Spring 2014 Private Securities Offering [Member]	'	'	'	'	'	'
Note 1 - Business and Organization (Details) [Line Items]	'	'	'	'	'	'
Proceeds From Issuance of Private Placement Net	'	'	245,000	'	'	'
Private Placement [Member]	'	'	'	'	'	'
Note 1 - Business and Organization (Details) [Line Items]	'	'	'	'	'	'
Proceeds from Issuance of Private Placement	'	'	1,505,644	'	'	'
Proceeds From Issuance of Private Placement Net	'	'	$1,475,644	'	'	'

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)

0 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

Jun. 08, 2010

Mar. 26, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Mar. 28, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Convertible Notes Payable [Member]

Patents [Member]

Officers [Member]

Officers [Member]

Third-Party Vendors [Member]

Third-Party Vendors [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

2007 Plan [Member]

2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Accrued and Unpaid Salary and Unreimbursed Expenses [Member]

Accrued and Unpaid Salary and Unreimbursed Expenses [Member]

Accrued and Unpaid Salary and Unreimbursed Expenses [Member]

Accrued and Unpaid Salary and Unreimbursed Expenses [Member]

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of Intangible Assets

'

'

$8,190

$8,190

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of Intangible Assets, Finite-lived

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

Allocated Share-based Compensation Expense

'

'

'

'

25,200

11,200

641,874

607,371

'

'

180,193

289,689

'

'

641,678

607,371

Stock Issued During Period, Shares, Other (in Shares)

'

'

'

'

'

'

'

'

'

'

336,967

965,660

'

'

'

'

Stock Issued During Period, Shares, Issued for Services (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

450,005

242,602

'

'

Stock Issued During Period, Value, Issued for Services

'

'

'

'

'

'

'

'

'

'

'

'

313,569

71,621

'

'

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

'

1,360,000

'

'

'

'

'

'

1,360,000

'

'

'

'

'

'

'

Debt Conversion, Converted Instrument, Amount

$100,000

$275,000

'

'

'

'

'

'

$584,800

'

'

'

'

'

'

'

Note_2_Summary_of_Significant_3

Note 2 - Summary of Significant Accounting Policies (Details) - Inventories (USD $)	Sep. 30, 2014	Dec. 31, 2013
Inventories [Abstract]	'	'
Raw materials	$57,044	$26,080
Finished goods	5,632	3,750
Total inventory	$62,676	$29,830

Note_3_Customer_Deposit_Detail

Note 3 - Customer Deposit (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Feb. 28, 2014	Sep. 30, 2014	Dec. 31, 2012
		Clarion Water [Member]	Clarion Water [Member]	Clarion Water [Member]	Product Ordered But Not Shipped [Member]	Peter Holdings Ltd. [Member]
		Beginning July 1, 2016 [Member]	Isan System License Agreement [Member]	Isan System License Agreement [Member]
		Isan System License Agreement [Member]	Licensing Agreements [Member]	Licensing Agreements [Member]
		Licensing Agreements [Member]	Peter Holdings Ltd. [Member]	Peter Holdings Ltd. [Member]
		Peter Holdings Ltd. [Member]
Note 3 - Customer Deposit (Details) [Line Items]	'	'	'	'	'	'
Joint Venture, Royalties, Percentage	'	'	'	'	'	50.00%
Customer Deposits, Current	$151,699	'	'	$100,000	$51,699	'
Royalty as Percentage of Sales	'	'	10.00%	'	'	'
Royalty as Percentage of Sublicensing Fees	'	'	40.00%	'	'	'
Quarterly Payments from Licensee	'	$50,000	'	'	'	'

Note_4_Private_Securities_Offe1

Note 4 - Private Securities Offerings (Details) (USD $)

1 Months Ended

9 Months Ended

16 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

10 Months Ended

8 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 28, 2012

Sep. 30, 2014

Sep. 30, 2013

Jun. 08, 2010

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Jun. 25, 2014

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Feb. 02, 2014

Jun. 14, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2013

Apr. 30, 2013

Dec. 17, 2012

Private Placement [Member]

Private Placement [Member]

Private Placement [Member]

Common Stock [Member]

Summer 2014 Offering [Member]

Summer 2014 Offering [Member]

Summer 2014 Offering [Member]

Summer 2013 [Member]

Summer 2013 [Member]

Clyra Spring 2014 Private Securities Offering [Member]

Clyra Spring 2014 Private Securities Offering [Member]

Winter 2013 [Member]

Clyra Winter 2012 Private Securities Offering [Member]

Clyra Winter 2012 Private Securities Offering [Member]

Clyra Winter 2012 Private Securities Offering [Member]

Clyra Winter 2012 Private Securities Offering [Member]

Clyra Winter 2012 Private Securities Offering [Member]

Summer 2013 [Member]

Summer 2013 [Member]

Clyra Spring 2014 Private Securities Offering [Member]

Note 4 - Private Securities Offerings (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Price Per Share

'

'

'

'

'

'

'

'

'

$0.40

$0.40

$0.40

'

$0.25

'

$1,000

$0.30

'

$1,000

'

'

'

Stock Issued During Period, Shares, New Issues

60,000

60,000

'

'

'

'

'

'

'

455,000

459,688

'

3,190,000

3,450,000

220

'

2,333,329

300,000

240

'

'

'

Proceeds from Issuance of Private Placement

'

'

'

'

'

'

'

$1,505,644

'

$182,000

'

'

$787,500

$862,500

$245,000

'

$700,000

'

$240,000

'

'

'

Proceeds From Issuance of Private Placement Net

'

'

'

'

'

'

'

1,475,644

'

162,000

'

'

'

857,000

'

'

633,000

'

236,000

'

'

'

Payments of Stock Issuance Costs

'

'

'

'

'

10,000

15,500

'

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issuance Cost Paid In Shares, Shares

'

'

'

'

'

'

'

'

'

4,688

'

'

138,400

'

'

'

'

'

'

'

'

'

Shares Issued, Price Per Share

'

'

'

'

'

'

'

'

'

$0.40

$0.40

'

$0.25

'

'

'

'

'

'

'

'

'

Stock Issued

'

'

'

'

'

'

'

'

'

'

'

'

$34,600

'

'

'

'

'

'

'

'

'

Common Stock, Shares Authorized

200,000,000

'

200,000,000

'

'

'

'

'

'

'

'

'

'

'

'

1,000

'

'

1,000

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

$0.30

$0.50

'

'

$0.50

'

'

'

'

'

'

'

'

'

$1,833.33

'

$0.55

'

'

'

$1,833

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

60,000

50,000

0

0

50,000

'

'

'

4,000

'

'

'

'

'

'

'

'

'

'

4,000

3,333

2,858

Note_5_Conversion_of_Notes_Det

Note 5 - Conversion of Notes (Details) (USD $)	0 Months Ended	1 Months Ended			9 Months Ended
	Jun. 08, 2010	Mar. 26, 2014	Dec. 31, 2013	Dec. 28, 2012	Sep. 30, 2014	Sep. 30, 2013	Nov. 15, 2013	Oct. 28, 2013	Dec. 31, 2012
Note 5 - Conversion of Notes (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	'	1,360,000	'	'	'	'	'	'	'
Debt Instrument, Convertible, Conversion Price (in Dollars per share)	'	$0.25	'	'	'	'	'	'	'
Debt Conversion, Converted Instrument, Amount	$100,000	$275,000	'	'	'	'	'	'	'
Interest Expense, Debt	'	'	'	15,000	9,828	0	'	'	'
Share Price (in Dollars per share)	'	$0.43	$0.25	$0.25	'	'	'	'	'
Derivative Liability, Fair Value, Amount Not Offset Against Collateral	'	244,800	'	6,805	'	'	'	'	14,412
Debt Instrument, Interest Rate, Stated Percentage	10.00%	'	'	'	'	'	10.00%	10.00%	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	50,000	'	60,000	50,000	0	0	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$0.50	'	$0.30	$0.50	'	'	'	'	'
Stock Issued During Period, Shares, New Issues (in Shares)	'	'	60,000	60,000	'	'	'	'	'
Debt Instrument, Face Amount	'	'	'	'	'	'	100,000	75,000	'
Convertible Debt [Member]	'	'	'	'	'	'	'	'	'
Note 5 - Conversion of Notes (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Interest Expense, Debt	'	$65,000	$15,000	'	$0	$7,556	'	'	'

Note_6_Warrants_Details

Note 6 - Warrants (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 28, 2012

Jun. 08, 2010

Aug. 29, 2014

Aug. 29, 2014

Sep. 30, 2014

Sep. 30, 2014

Mar. 31, 2014

Mar. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Apr. 30, 2013

Apr. 30, 2013

Dec. 31, 2012

Mar. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2014

Jun. 25, 2014

Clyra Common Stock [Member]

BioLargo Common Stock [Member]

Summer 2014 Offering [Member]

Summer 2013 [Member]

Summer 2013 [Member]

Summer 2013 [Member]

Clyra Spring 2014 Private Securities Offering [Member]

Clyra Spring 2014 Private Securities Offering [Member]

Clyra Winter 2012 Private Securities Offering [Member]

Clyra Winter 2012 Private Securities Offering [Member]

Clyra Winter 2012 Private Securities Offering [Member]

Winter 2013 [Member]

Winter 2012 Warrants [Member]

Winter 2012 Warrants [Member]

Winter 2012 Warrants [Member]

Other Warrants [Member]

Other Warrants [Member]

Summer 2014 Offering [Member]

Summer 2014 Offering [Member]

Clyra Winter 2012 Private Securities Offering [Member]

Clyra Winter 2012 Private Securities Offering [Member]

Common Stock [Member]

June 2013 through March 2014 [Member]

Common Stock [Member]

Modified Offering [Member]

Common Stock [Member]

Note 6 - Warrants (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

0

60,000

0

'

50,000

50,000

'

'

455,500

'

3,370,000

3,190,000

4,000

980,000

4,000

960,000

2,858

1,366,664

'

'

3,127,914

'

60,000

'

'

Sale of Stock, Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.40

$0.40

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

'

$0.30

'

'

$0.50

$0.50

'

'

$0.75

'

'

$0.30

'

'

'

$1,833

'

$0.55

'

'

$0.50

'

$0.30

'

'

Class of Warrant or Right, Call Provision, Stock Price Threshold, Consecutive Business Days

'

'

'

'

'

'

'

'

'20 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Call Provision, Stock Price Threshold (in Dollars per share)

'

'

'

'

'

'

'

'

$1.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

280,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Warrant Exercises (in Dollars)

'

'

'

'

'

'

'

'

'

$84,000

'

'

'

'

'

'

'

'

$197,144

'

'

'

'

'

'

Conversion of Stock, Shares Converted

'

'

'

'

'

'

75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Stock, Shares Issued

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

394,288

'

'

'

'

'

'

Class of Warrant or Right, Outstanding

8,438,122

10,618,771

9,718,772

8,390,741

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,533,626

'

'

'

'

'

Interest Expense, Other (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$14,412

'

'

'

Note_6_Warrants_Details_Warran

Note 6 - Warrants (Details) - Warrants Outstanding (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Class of Warrant or Right [Line Items]	'	'
Outstanding as of December 31, (in Shares)	10,618,771	8,390,741
Issued (in Shares)	4,785,001	2,603,329
Exercised (in Shares)	-674,288	'
Expired (in Shares)	-6,291,362	-1,275,298
Outstanding as of June 30, (in Shares)	8,438,122	9,718,772
Minimum [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Outstanding as of December 31,	0.125	0.125
Issued	0.25	0.5
Exercised	0.3	'
Expired	0.5	0.5
Outstanding as of June 30,	0.125	0.125
Maximum [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Outstanding as of December 31,	1	2
Issued	1	1
Exercised	0.5	'
Expired	1	1
Outstanding as of June 30,	1	1

Note_6_Warrants_Details_Assump

Note 6 - Warrants (Details) - Assumptions Used to Determine Fair Value of Warrants (Warrant [Member])	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
	Minimum [Member]	Maximum [Member]
Note 6 - Warrants (Details) - Assumptions Used to Determine Fair Value of Warrants [Line Items]	'	'	'
Risk free interest rate	9.00%	1.55%	0.12%
Expected volatility	184.00%	349.00%	113.00%
Contractual life in years	'1 year	'5 years	'1 year

Note_7_Stockholders_Equity_Det

Note 7 - Stockholders' Equity (Details)

1 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

Dec. 31, 2013

Dec. 28, 2012

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Summer 2013 Offering [Member]

Conversion of Notes Payables [Member]

Summer 2014 Offering [Member]

Summer 2014 Offering [Member]

2012 Warrants [Member]

Clyra Winter 2012 Private Securities Offering [Member]

Clyra Winter 2012 Private Securities Offering [Member]

Summer 2013 Warrants [Member]

Accrued and Unpaid Obligations [Member]

Third-Party Vendors [Member]

Note 7 - Stockholders' Equity (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Outstanding

0

'

0

'

'

'

'

'

'

'

'

'

'

Common Stock, Shares, Outstanding

75,123,014

'

82,074,237

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, New Issues

60,000

60,000

'

3,328,400

1,360,000

455,000

459,688

394,288

300,000

240

280,000

336,967

450,005

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

'

'

41,875

'

'

'

'

'

'

'

'

'

'

Note_8_StockBased_Compensation2

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) (USD $)

9 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 29, 2014

Mar. 31, 2014

Sep. 29, 2014

Sep. 30, 2013

Jun. 23, 2014

Mar. 31, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Jun. 23, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 29, 2014

Mar. 31, 2014

Mar. 31, 2014

Jun. 17, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 29, 2014

Jun. 23, 2014

Mar. 31, 2014

Sep. 29, 2014

Jun. 24, 2014

Mar. 31, 2014

Sep. 30, 2013

Sep. 29, 2014

Sep. 30, 2013

Jun. 23, 2014

Mar. 31, 2014

Jun. 23, 2014

Jun. 23, 2014

Sep. 30, 2013

Jun. 23, 2014

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 29, 2014

Feb. 20, 2014

Sep. 30, 2014

Sep. 30, 2013

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expense [Member]

Board of Directors [Member]

Board of Directors [Member]

Board of Directors [Member]

Board of Directors [Member]

Board of Directors [Member]

Board of Directors [Member]

Board of Directors [Member]

Board of Directors [Member]

Board of Directors [Member]

Board of Directors [Member]

Board of Directors [Member]

Vendors and Consultants [Member]

Vendors and Consultants [Member]

Vendors and Consultants [Member]

Vendors and Consultants [Member]

Vendors and Consultants [Member]

Vendors and Consultants [Member]

Vendors and Consultants [Member]

Vendors and Consultants [Member]

Board of Directors Chairman [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Nonemployee Members of the Board [Member]

Nonemployee Members of the Board [Member]

Consultants [Member]

Holder of a Stock Option [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Board of Directors [Member]

Board of Directors [Member]

Board of Directors [Member]

Vendors and Consultants [Member]

Vendors and Consultants [Member]

Vendors and Consultants [Member]

Vendors and Consultants [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

Nonemployee Members of the Board [Member]

Consultants [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Board of Directors [Member]

Number of Shares Per Member [Member]

Number of Shares Per Member [Member]

Accrued and Unpaid Obligations [Member]

Accrued and Unpaid Obligations [Member]

Accrued and Unpaid Obligations [Member]

2007 Equity Incentive Plan [Member]

2007 Equity Incentive Plan [Member]

2007 Equity Incentive Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Accrued and Unpaid Obligations [Member]

Accrued and Unpaid Obligations [Member]

Accrued and Unpaid Obligations [Member]

Accrued and Unpaid Obligations [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Accrued and Unpaid Obligations [Member]

Vesting Monthly [Member]

Portion of Options Vested [Member]

Outside of the 2007 Plan [Member]

Accrued and Unpaid Obligations [Member]

Outside of the 2007 Plan [Member]

Portion of Options Vested [Member]

Outside of the 2007 Plan [Member]

2007 Equity Incentive Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

2007 Equity Incentive Plan [Member]

2007 Equity Incentive Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

40,000

40,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

10,000

'

'

156,888

'

40,000

40,000

143,617

103,847

'

'

'

'

'

193,511

1,033,825

148,848

78,488

'

'

'

300,000

'

675,000

'

41,875

40,000

1,165,199

2,008,825

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$0.63

$0.28

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.43

$0.28

$0.63

'

$0.47

$0.65

'

'

'

'

'

$0.47

$0.30

$0.65

$0.43

'

'

'

$0.63

'

$0.30

'

'

$0.35

'

$0.30

Allocated Share-based Compensation Expense

'

'

$25,200

$22,500

$22,461

$23,450

$82,706

$32,250

$11,250

$141,000

$52,500

$54,000

$57,000

$641,874

$607,371

$22,501

'

'

'

'

'

$11,200

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$641,678

$607,371

Other Liabilities, Current

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45,000

45,000

'

'

'

'

'

'

'

67,500

64,500

22,500

206,765

'

'

'

'

45,000

'

'

'

135,000

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

'

'

'

'

'

$90,950

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$67,500

$67,501

$67,461

'

'

'

'

'

$289,471

$96,750

$33,750

'

'

'

'

'

$189,000

'

'

$14,000

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

300,000

'

'

'

800,000

'

'

'

'

Note_8_StockBased_Compensation3

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Activity for our Stock Options (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
			Minimum [Member]	Minimum [Member]	Minimum [Member]	Minimum [Member]	Maximum [Member]	Maximum [Member]	Maximum [Member]	Maximum [Member]
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Activity for our Stock Options [Line Items]	'	'	'	'	'	'	'	'	'	'
Options Outstanding (in Shares)	8,561,086	8,518,418	'	'	'	'	'	'	'	'
Shares Available (in Shares)	4,420,742	4,260,742	'	'	'	'	'	'	'	'
Price per share	'	'	$0.23	$0.23	$0.23	$0.23	$1.89	$1.89	$1.89	$1.89
Weighted Average Price per share	$0.44	$0.44	'	'	'	'	'	'	'	'
Options Outstanding (in Shares)	40,000	40,000	'	'	'	'	'	'	'	'
Shares Available (in Shares)	-40,000	-40,000	'	'	'	'	'	'	'	'
Price per share	$0.63	$0.28	'	'	'	'	'	'	'	'
Weighted Average Price per share	$0.63	$0.28	'	'	'	'	'	'	'	'
Options Outstanding (in Shares)	8,601,086	8,561,086	'	'	'	'	'	'	'	'
Shares Available (in Shares)	4,380,742	4,420,742	'	'	'	'	'	'	'	'
Price per share	'	'	$0.23	$0.23	$0.23	$0.23	$1.89	$1.89	$1.89	$1.89
Weighted Average Price per share	$0.44	$0.44	'	'	'	'	'	'	'	'

Note_8_StockBased_Compensation4

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Options Issued Outside of 2007 Equity Plan (USD $)

9 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2014

Jan. 01, 2014

Sep. 30, 2013

Jan. 01, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2014

Jan. 01, 2014

Sep. 30, 2013

Jan. 01, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2013

Dec. 31, 2012

Feb. 20, 2014

Sep. 30, 2014

Sep. 30, 2013

Jan. 01, 2014

Jan. 01, 2013

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Outside of the 2007 Plan [Member]

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Options Issued Outside of 2007 Equity Plan [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options Outstanding, balance (in Shares)

8,601,086

8,561,086

8,561,086

8,518,418

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

17,521,719

15,347,045

16,398,395

13,338,220

Price per share, balance

'

'

'

'

$0.18

$0.18

$0.18

$0.18

$0.23

$0.23

$0.23

$0.23

$1

$1

$1.89

$1.89

$1.89

$1.89

$1.89

$1.89

'

'

'

'

'

Weighted Average Price per Share, balance

$0.44

$0.44

$0.44

$0.44

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.40

$0.36

$0.39

$0.41

Options Outstanding, granted (in Shares)

40,000

40,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

40,000

1,165,199

2,008,825

'

'

Price per share, granted

$0.63

$0.28

'

'

$0.43

'

'

'

'

'

'

'

$0.65

'

'

'

'

'

'

'

'

'

$0.30

'

'

Weighted Average Price per Share, granted

$0.63

$0.28

'

'

$0.43

'

'

'

'

'

'

'

$0.65

'

'

'

'

'

'

'

$0.35

'

$0.30

'

'

Options Outstanding, exercised (in Shares)

-41,875

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-41,875

'

'

'

Price per share, exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.30

'

'

'

Weighted Average Price per Share, exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.30

'

'

'

Note_8_StockBased_Compensation5

Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options, Valuation Assumptions	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Minimum [Member] | Non Plan [Member]	'	'
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options, Valuation Assumptions [Line Items]	'	'
Risk free interest rate	2.54%	2.64%
Expected volatility	908.00%	'
Maximum [Member] | Non Plan [Member]	'	'
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options, Valuation Assumptions [Line Items]	'	'
Risk free interest rate	2.73%	2.66%
Expected volatility	935.00%	'
Non Plan [Member]	'	'
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options, Valuation Assumptions [Line Items]	'	'
Expected volatility	'	928.00%
Expected life in years	'7 years	'7 years
2007 Plan [Member]	'	'
Note 8 - Stock-Based Compensation and Other Employee Benefit Plans (Details) - Stock Options, Valuation Assumptions [Line Items]	'	'
Risk free interest rate	2.63%	2.19%
Expected volatility	927.00%	928.00%
Expected life in years	'7 years	'7 years

Note_9_Accounts_Payable_and_Ac2

Note 9 - Accounts Payable and Accrued Expenses (Details) (USD $)

3 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Mar. 26, 2014

Dec. 31, 2013

Dec. 28, 2012

Sep. 27, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 27, 2013

Sep. 29, 2014

Jun. 26, 2014

Sep. 29, 2014

Jun. 26, 2014

Sep. 29, 2014

Sep. 29, 2014

Sep. 29, 2014

Sep. 29, 2014

Sep. 29, 2014

Sep. 29, 2014

Jun. 30, 2014

Jun. 24, 2014

Jun. 30, 2014

Jun. 24, 2014

Jun. 24, 2014

Jun. 24, 2014

Mar. 28, 2014

Mar. 28, 2014

Mar. 28, 2014

Mar. 28, 2014

Sep. 29, 2014

Jun. 24, 2014

Mar. 28, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 29, 2014

Jun. 24, 2014

Mar. 28, 2014

Sep. 30, 2013

Sep. 30, 2013

15-May-13

Jan. 04, 2013

15-May-13

Jan. 04, 2013

15-May-13

15-May-13

Vendors and Consultants [Member]

Vendors and Consultants [Member]

Vendors and Consultants [Member]

Vendors and Consultants [Member]

Company Providing Ongoing Services [Member]

Company Providing Ongoing Services [Member]

Company Providing Ongoing Services [Member]

Company Providing Ongoing Services [Member]

Consultant 1 [Member]

Consultant 1 [Member]

Other Company Providing Ongoing Services [Member]

Other Company Providing Ongoing Services [Member]

Consultant 2 [Member]

Consultant 2 [Member]

Vendor [Member]

Vendor [Member]

Vendor [Member]

Vendor [Member]

Consultant [Member]

Consultant [Member]

2 Vendors [Member]

2 Vendors [Member]

Two Other Vendors [Member]

Two Other Vendors [Member]

Officer [Member]

Officer [Member]

Officer [Member]

Officer [Member]

Officer [Member]

Officer [Member]

Officer [Member]

Officer [Member]

Three Executive Officers [Member]

Three Executive Officers [Member]

Selling, General and Administrative Expense [Member]

Selling, General and Administrative Expense [Member]

Selling, General and Administrative Expense [Member]

Selling, General and Administrative Expense [Member]

Selling, General Administrative Expense and Prepaid Rent [Member]

Selling, General Administrative Expense and Prepaid Rent [Member]

Note 9 - Accounts Payable and Accrued Expenses (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued for Services (in Shares)

'

'

'

'

'

'

'

135,826

450,005

242,602

'

56,250

90,000

'

'

52,127

'

17,094

'

11,324

'

31,096

18,594

'

'

11,539

'

73,444

'

88,537

'

114,015

139,458

83,493

336,967

965,660

'

'

'

965,660

'

11,112

42,092

'

'

53,572

'

Selling, General and Administrative Expense

$652,432

$536,026

$2,208,461

$1,470,936

'

'

'

$37,091

$313,569

$71,621

'

$22,500

$22,500

'

'

$15,638

'

$10,725

'

$10,605

'

$25,000

$10,725

'

'

$7,500

'

$18,225

'

$38,070

'

$53,586

$90,705

$35,902

$180,193

$289,698

'

'

'

$289,698

'

$3,111

$10,530

'

'

$11,425

'

Shares Issued, Price Per Share (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

$0.27

'

'

$0.40

$0.25

'

$0.30

'

$0.63

'

'

'

'

$0.80

'

'

'

'

$0.25

'

$0.43

'

'

'

'

'

'

'

'

'

$0.30

'

'

$0.28

$0.25

'

$0.28

Share Price (in Dollars per share)

'

'

'

'

$0.43

$0.25

$0.25

'

'

'

'

'

'

$0.47

$0.63

'

$0.47

'

$0.47

'

$0.47

'

'

'

$0.65

'

$0.65

'

$0.43

'

'

'

'

'

'

'

$0.47

$0.65

$0.43

'

'

'

'

'

'

'

'

Agreement With Vendor, Average Common Stock Price, Number of Days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'20 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other General Expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000

'

Prepaid Rent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,575

Note_9_Accounts_Payable_and_Ac3

Note 9 - Accounts Payable and Accrued Expenses (Details) - Accounts Payable and Accrued Expenses (USD $)	Sep. 30, 2014	Dec. 31, 2013
Accounts Payable and Accrued Expenses [Abstract]	'	'
Accounts payable and accrued expenses	$393,361	$362,194
Accrued interest	10,119	18,226
Officer and board of director payables	17,450	26,737
Total accounts payable and accrued expenses	$420,930	$407,157

Note_10_Note_Payable_Details

Note 10 - Note Payable (Details) (USD $)	1 Months Ended		9 Months Ended
	Nov. 19, 2013	Dec. 28, 2012	Sep. 30, 2014	Sep. 30, 2013
Disclosure Text Block [Abstract]	'	'	'	'
Proceeds from Lines of Credit	$50,000	'	'	'
Line of Credit Facility, Interest Rate at Period End	24.00%	'	'	'
Interest Expense, Debt	'	$15,000	$9,828	$0

Note_11_NonControlling_Interes1

Note 11 - Non-Controlling Interest (Details) (USD $)	1 Months Ended		9 Months Ended	0 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 28, 2012	Sep. 30, 2014	Dec. 17, 2012	Sep. 30, 2014	Dec. 31, 2013	31-May-12
				Each of 3 Individuals [Member]	Clyra Medical Technology, Inc. [Member]	Clyra Medical Technology, Inc. [Member]	Clyra Medical Technology, Inc. [Member]
				Clyra Medical Technology, Inc. [Member]
Note 11 - Non-Controlling Interest (Details) [Line Items]	'	'	'	'	'	'	'
Investment Owned, Balance, Shares	'	'	'	'	'	'	7,500
Stock Issued During Period, Shares, New Issues	60,000	60,000	'	500	'	'	'
Stock Issued During Period, Value, New Issues (in Dollars)	'	'	'	'	$245,000	$236,000	'
Sale of Stock, Number of Shares Issued in Transaction	'	'	'	'	245	240	'
Sale of Stock, Percentage of Ownership after Transaction	'	'	19.60%	'	'	'	'